Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis
Scott D. Sagel, Phuong T. Vu, Sonya L. Heltshe, George M. Solomon, Andrea Kelly, Jessica E. Pittman, Margaret Rosenfeld, Félix Ratjen
Topics & Concepts
MedicineCystic fibrosisRespiratory systemInternal medicineRespiratory diseaseReduction (mathematics)GastroenterologyTonicityIntensive care medicineHypertonic salineCystic Fibrosis Research AdvancesAsthma and respiratory diseasesSinusitis and nasal conditions